Science News
from research organizations
Added benefit of saxagliptin as monotherapy not proven
- Date:
- December 5, 2013
- Source:
- Institute for Quality and Efficiency in Health Care
- Summary:
- Although the drug manufacturer presented studies for an indirect comparison with sulfonylurea, these were unsuitable because they did not investigate the right patient group. The added benefit of saxaglipton as a monotherapy has not been proven.
- Share:
FULL STORY
The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin is not tolerated or cannot be used.
Story Source:
Materials provided by Institute for Quality and Efficiency in Health Care. Note: Content may be edited for style and length.
Cite This Page:
Institute for Quality and Efficiency in Health Care. "Added benefit of saxagliptin as monotherapy not proven." ScienceDaily. ScienceDaily, 5 December 2013. <www.sciencedaily.com
Institute for Quality and Efficiency in Health Care. (2013, December 5). Added benefit of saxagliptin as monotherapy not proven. ScienceDaily. Retrieved August 31, 2025 from www.sciencedaily.com
Institute for Quality and Efficiency in Health Care. "Added benefit of saxagliptin as monotherapy not proven." ScienceDaily. www.sciencedaily.com
Explore More
from ScienceDaily
RELATED STORIES